akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2070-4968.2015.9.2.099-109akusherstvo-162Research ArticleREVIEW ARTICLEНАУЧНЫЙ ОБЗОРPathogenesis of Trousseau’s syndromeВОПРОСЫ ПАТОГЕНЕЗА СИНДРОМА ТРУССОВоробьевА. В.VorobevA. V.

к.м.н., доцент кафедры акушерства и гинекологии медико-профилактического факультета

MD, Ph.D., Associate Professor, Department of Obstetrics and Gynecology

alvorobev@gmail.comЧабровА. М.ChabrovA. M.

к.м.н., заведующий гинекологическим отделением

MD, Ph.D., head of gynecological department

СавченкоА. А.MD, Ph.D., head of gynecological departmentA. A.

к.м.н., врач гинекологического отделения

MD, Ph.D., gynecological department

БулгаковаС. В.BulgakovaS. V.

к.м.н., врач гинекологического отделения

MD, Ph.D., gynecological department

МакацарияА. Д.MakatsariyaA. D.

д.м.н., член-корреспондент РАН, профессор, заведующий кафедрой акушерства и гинекологии медико-профилактического факультета

MD, corresponding member of the Russian Academy of Sciences, Professor, Head of the Department of Obstetrics and Gynecology

gemostasis@mail.ruГБОУ ВПО «Первый МГМУ имени И.М. Сеченова» Минздрава России, МоскваРоссияFirst Moscow State Medical Sechenov University of the Ministry of Health Russian FederationRussian Federation2015190620169299109Copyright © Vorobev A.V., Chabrov A.M., MD, Ph.D., head of gynecological department A.A., Bulgakova S.V., Makatsariya A.D., 20162016Воробьев А.В., Чабров А.М., Савченко А.А., Булгакова С.В., Макацария А.Д.Vorobev A.V., Chabrov A.M., MD, Ph.D., head of gynecological department A.A., Bulgakova S.V., Makatsariya A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/162Синдром Труссозлокачественные новообразованиятромботические осложнениясистема гемостазаметастази- рование опухолевой тканиДВС-синдромтромбофилияпатогенез тромботических осложненийонкологические больныепрофилактика тромбозовнарушения гемостазаTrousseau’s syndromemalignanciesthrombotic complicationshemostasis systemmetastasis of tumor tissueDICthrombophiliapathogenesis of thrombotic complicationscancer patientsprevention of thrombosishemostasis disordersReferencesВоробьев А.В. Состояние тромбоцитарного звена гемостаза у онкогинекологических больных. Материалы VI российского форума «Мать и дитя». 2004: 318-319.Vorob'ev A.V. Status platelet hemostasis in patients with gynecological cancer. Proceedings of the VI Russian forum «Mother and Child» [Sostoyanie trombotsitarnogo zvena gemostaza u onkoginekologicheskikh bol’nykh. Materialy VI rossiiskogo foruma «Mat’ i ditya». (in Russian)]. 2004: 318-319.Макацария А.Д., Воробьев А.В., Бицадзе В.О. Злокачественные новообразования, тромбо- филия, тромбозы. Монография. М. 2008; 650 с.Makatsariya A.D., Vorob’ev A.V., Bitsadze V.O. Malignancies, thrombophilia, thrombosis. Monograph [Zlokachestvennye novoobrazovaniya, trombofiliya, trombozy. Monografiya. (in Russian)]. Moscow. 2008; 650 s.Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложне- ний. Ассоциация флебологов России, Всероссийское общество хирургов. М. 2010.Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic complications. Phlebology Association of Russia, Russian Society of Surgeons [Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii. Assotsiatsiya flebologov Rossii, Vserossiiskoe obshchestvo khirurgov. (in Russian)]. Moscow. 2010Цыб А.Ф., Сушкевич Г.Н., Балуда М.В., Воро- бьев А.В., Чабров А.М. Принципы профилактики тромботических осложнений у онколо- гических больных (солидные образования). Пособие для врачей. Обнинск. 2008; 42 с.Tsyb A.F., Sushkevich G.N., Baluda M.V., Vorob'ev A.V., Chabrov A.M. The principles of prevention of thrombotic events in patients with cancer (solid education). Manual for physicians [Printsipy profilaktiki tromboticheskikh oslozhnenii u onkologicheskikh bol’nykh (solidnye obrazovaniya). Posobie dlya vrachei. (in Russian)]. Obninsk. 2008; 42 s.Bharthuar A., Khorana A.A., Hutson A. et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. 2013; 132: 180-184.Bharthuar A., Khorana A.A., Hutson A. et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. 2013; 132: 180-184.Chaturvedi S., Sidana S., Elson R., Khorana A.A., McCrae K.R. Symptomatic and incidental venousthromboembolic disease are both associated withmortality in patients with prostate cancer. PLoSOne 2014; 9: e94048.Chaturvedi S., Sidana S., Elson R., Khorana A.A., McCrae K.R. Symptomatic and incidental venousthromboembolic disease are both associated withmortality in patients with prostate cancer. PLoSOne 2014; 9: e94048.Claussen C., Rausch A.V., Spath B. et al. Clinical significance of hemostatic activation markers inwomen with suspected ovarian cancer. Oncol Res Treat. 2014; 37: 669.Claussen C., Rausch A.V., Spath B. et al. Clinical significance of hemostatic activation markers inwomen with suspected ovarian cancer. Oncol Res Treat. 2014; 37: 669.Dammacco F., Vacca A., Procaccio P. et al. Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a singlecenter of internal medicine. ClinExp Med 2013; 13: 85-97.Dammacco F., Vacca A., Procaccio P. et al. Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a singlecenter of internal medicine. ClinExp Med 2013; 13: 85-97.Davila M., Robles-Carrillo L., Unruh D. et al. Microparticle association and heterogeneity oftumor-derived tissue factor in plasma: is it important for coagulation activation? ThrombHaemost. 2014; 12: 186-196.Davila M., Robles-Carrillo L., Unruh D. et al. Microparticle association and heterogeneity oftumor-derived tissue factor in plasma: is it important for coagulation activation? ThrombHaemost. 2014; 12: 186-196.Demers M., Wagner D.D. NETosis: a new factor intumor progression and cancer-associated thrombosis. SeminThrombHemost. 2014; 40: 277-283.Demers M., Wagner D.D. NETosis: a new factor intumor progression and cancer-associated thrombosis. SeminThrombHemost. 2014; 40: 277-283.Fuchs T.A., Brill A., Wagner D.D. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. ArteriosclerThromb Vase Biol. 2012; 32: 1777-1783.Fuchs T.A., Brill A., Wagner D.D. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. ArteriosclerThromb Vase Biol. 2012; 32: 1777-1783.Geddings J.E., Mackman N. Tumor-derived tissuefactor-positive microparticles and venous thrombosisincancer patients. Blood. 2013; 122: 1873-1880.Geddings J.E., Mackman N. Tumor-derived tissuefactor-positive microparticles and venous thrombosisincancer patients. Blood. 2013; 122: 1873-1880.Hernandez C., Orbe J., Roncal C. et al. Tissue factorexpressed by microparticles is associated withmortality but not with thrombosis in cancer patients. ThrombHaemost. 2013; 110: 598-608.Hernandez C., Orbe J., Roncal C. et al. Tissue factorexpressed by microparticles is associated withmortality but not with thrombosis in cancer patients. ThrombHaemost. 2013; 110: 598-608.Hyman D.M., Soff G.A., Kampel L.J. Disseminatedintravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review ofthe literature. Oncology. 2011; 81: 119-125.Hyman D.M., Soff G.A., Kampel L.J. Disseminatedintravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review ofthe literature. Oncology. 2011; 81: 119-125.Khorana AA. Risk assessment for cancerassociated thrombosis: what is the best approach? Thromb Res. 2012; 129: 10-15.Khorana AA. Risk assessment for cancerassociated thrombosis: what is the best approach? Thromb Res. 2012; 129: 10-15.Kitchens C.S. The contact system. Arch Pathol Lab Med. 2002 Nov; 126 (11): 1382-6.Kitchens C.S. The contact system. Arch Pathol Lab Med. 2002 Nov; 126 (11): 1382-6.Kocatiirk B., Versteeg H.H. Tissue factor isoformsin cancer and coagulation: may the best isoformwin. Thromb Res 2012; 129: 69-75.Kocatiirk B., Versteeg H.H. Tissue factor isoformsin cancer and coagulation: may the best isoformwin. Thromb Res 2012; 129: 69-75.Langer F., Bokemeyer C. Crosstalk between cancerand haemostasis. Implications for cancer biologyand cancer-associated thrombosis with focus ontissue factor. Hamostaseologie. 2012; 32: 95-104.Langer F., Bokemeyer C. Crosstalk between cancerand haemostasis. Implications for cancer biologyand cancer-associated thrombosis with focus ontissue factor. Hamostaseologie. 2012; 32: 95-104.Lo L., Valentine H., Harrison J. et al. Tissue factorexpression in the metaplasia-adenomacarcinomasequence of gastric cancer in a European population. Br I Cancer. 2012; 107: 1125-1130Lo L., Valentine H., Harrison J. et al. Tissue factorexpression in the metaplasia-adenomacarcinomasequence of gastric cancer in a European population. Br I Cancer. 2012; 107: 1125-1130Mackman N. New insights into the mechanisms ofvenous thrombosis. J Clin Invest. 2012; 122: 2331-2336.Mackman N. New insights into the mechanisms ofvenous thrombosis. J Clin Invest. 2012; 122: 2331-2336.Rak J., Yu J.L., Luyendyk J., Mackman N. Oncogenes, trousseau syndrome, and cancerrelated changesin the coagulome of mice and humans. Cancer Res. 2006: 66: 10643-10646.Rak J., Yu J.L., Luyendyk J., Mackman N. Oncogenes, trousseau syndrome, and cancerrelated changesin the coagulome of mice and humans. Cancer Res. 2006: 66: 10643-10646.Sack G.H. Jr, Levin J., Bell W.R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeuticfeatures. Medicine (Baltimore) 1977; 56: 1-37.Sack G.H. Jr, Levin J., Bell W.R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeuticfeatures. Medicine (Baltimore) 1977; 56: 1-37.Thaler J., Preusser M., Ay C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res. 2013; 131: 162-165.Thaler J., Preusser M., Ay C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res. 2013; 131: 162-165.Thaler I., Ay C., Mackman N. et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathologicalfeatures. Eur I Clin Invest. 2013; 43: 277-285.Thaler I., Ay C., Mackman N. et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathologicalfeatures. Eur I Clin Invest. 2013; 43: 277-285.Trousseau A. Phlegmasiaalbadolens. Clinique Medicale de l'Hotel-Dieu de Paris. 1865; 3: 654-712.Trousseau A. Phlegmasiaalbadolens. Clinique Medicale de l'Hotel-Dieu de Paris. 1865; 3: 654-712.Varki A. Trousseaus syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110; 1723-1729.Varki A. Trousseaus syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110; 1723-1729.Vorobiev A.V., Makatsaria A.D., Chabrov A.M. Thrombophilia markers in cancer patients during chemotherapy and radiation therapy. Pathophysiology of haemostasis and thrombosis. 2006; 35 (1-2): A20.Vorobiev A.V., Makatsaria A.D., Chabrov A.M. Thrombophilia markers in cancer patients during chemotherapy and radiation therapy. Pathophysiology of haemostasis and thrombosis. 2006; 35 (1-2): A20.Van Doormaal F.K. Terpstra W., Van Der Griend Ret al. Is extensive screening for cancer in idiopathicvenous thromboembolism warranted? J ThrombHaemost. 2011; 9: 79-84.Van Doormaal F.K. Terpstra W., Van Der Griend Ret al. Is extensive screening for cancer in idiopathicvenous thromboembolism warranted? J ThrombHaemost. 2011; 9: 79-84.

The authors declare that there are no conflicts of interest present.